본문 바로가기
KERD
논문KCI 등재

Strategy to Overcome Drug Resistance That Develops during Treatment of Chronic Hepatitis B in Children

Byung-Ho Choe|Suk Jin Hong
대한소아소화기영양학회 (The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition)|2012.06|Pediatric Gastroenterology, Hepatology & Nutrition|제15권 제2호|pp. 63-73|DOI http://dx.doi.org/

1

조회

0

다운로드

1

인용

0

참고문헌

키워드

ChildrenDrug resistanceAntiviral agentsChronic hepatitis B
주제분류소아과학

초록

Development of antiviral resistance to lamivudine is the most important factor for the treatment failure. It is necessary to establish proper guidelines to overcome drug resistance for children with chronic hepatitis B. Primary treatment with lamivudine should be considered if patients are in immune-clearance phase and have persistently elevated ALT levels more than twice the upper limit of normal value. Before initiating the therapy, careful consideration of the patient’s status is required to exclude abnormal liver function tests due to other causes. The treatment option should be carefully decided to suppress the viral replication effectively. To obtain good compliance, clinicians should educate patients and their parents. Appropriate monitoring for virologic breakthrough and genotypic resistance is important in deciding to change the treatment plan. Sequential monotherapy should be avoided and a combination of drugs in other categories is recommended. New antiviral agents, such as entecavir and tenofovir, which have high potency and high genetic barrier, are soon expected to be available for use with children.

Abstract

Development of antiviral resistance to lamivudine is the most important factor for the treatment failure. It is necessary to establish proper guidelines to overcome drug resistance for children with chronic hepatitis B. Primary treatment with lamivudine should be considered if patients are in immune-clearance phase and have persistently elevated ALT levels more than twice the upper limit of normal value. Before initiating the therapy, careful consideration of the patient’s status is required to exclude abnormal liver function tests due to other causes. The treatment option should be carefully decided to suppress the viral replication effectively. To obtain good compliance, clinicians should educate patients and their parents. Appropriate monitoring for virologic breakthrough and genotypic resistance is important in deciding to change the treatment plan. Sequential monotherapy should be avoided and a combination of drugs in other categories is recommended. New antiviral agents, such as entecavir and tenofovir, which have high potency and high genetic barrier, are soon expected to be available for use with children.

참고문헌 (78)

  1. 최병호, "한국 소아 B형 간염의 역학과 현황", Korean Journal of Pediatrics, 51(7), pp.696~703 (2008), 대한소아과학회
  2. "KASL Guidelines for Treatment of Chronic Hepatitis B", The Korean Association for the Study of the Liver, ~ (2011)
  3. Park HJ, "The rate of converting to immune-clearance phase from immune-tolerant phase in children with chronic hepatitis B", The 61st annual fall meeting of the Korea Pediatric Society, pp.230~ (2011)
  4. Shah U, "Management of chronic hepatitis B in children", J Pediatr Gastroenterol Nutr, 48, pp.399~404 (2009)
  5. Jennuvat S, "Hepatocellular carcinoma in children presents with massive upper gastrointestinal bleeding: a case report", J Med Assoc Thai, 94(3), pp.222~225 (2011)
  6. Hsu HC, "Childhood hepatocellular carcinoma develops exclusively in hepatitis B surface antigen carriers in three decades in Taiwan. Report of 51 cases strongly associated with rapid development of liver cirrhosis", J Hepatol, 5, pp.260~267 (1987)
  7. Lee HC, "Primary hepatic tumors in children: Clinical experience in a single institution", Korean J Pediatr Hematol Oncol, 7, pp.269~277 (2000)
  8. Bortolotti F, "Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study", Hepatology, 43, pp.556~562 (2006)
  9. Kim JO, "Long-term lamivudine treatment in children and adolescence with chronic hepatitis B: predictors of therapeutic response and lamivudine resistance", Asian Pacific Association for the Study of the Liver (APASL), pp.220~ (2008)
  10. Torre D TR, "Interferon-alpha therapy for chronic hepatitis B in children: a meta-analysis", Clin Infect Dis, 23, pp.131~137 (1996)
  11. Jonas MM, "Clinical trial of lamivudine in children with chronic hepatitis B", N Engl J Med, 346, pp.1706~1713 (2002)
  12. Chang MH, "Hepatitis B virus integration in hepatitis B virus-related hepatocellular carcinoma in childhood", Hepatology, 13, pp.316~320 (1991)
  13. 최병호, "만성 B형 간염 상담: 국내 인터넷 상의 흔한 오류를 중심으로", Pediatric Gastroenterology, Hepatology & Nutrition, 11(1), pp.1~11 (2008), 대한소아소화기영양학회
  14. Lai CL, "Placebo-controlled trial of recombinant alpha 2-interferon in Chinese HBsAg-carrier children", Lancet, 2, pp.877~880 (1987)
  15. Hom X, "Predictors of virologic response to Lamivudine treatment in children with chronic hepatitis B infection", Pediatr Infect Dis J, 23, pp.441~445 (2004)
  16. Kim JS PS, "Predictors of response to lamivudine treatment in children with chronic hepatitis B", Chonnam Med J, 44, pp.37~42 (2008)
  17. Sokal EM, "Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial", Gastroenterology, 114, pp.988~995 (1998)
  18. Choe BH, "Lamivudine treatment in children with chronic hepatitis B: Long-term therapeutic response, optimal duration and resistance", the 39th Annual Meeting of European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN), pp.47~ (2006)
  19. Jonas MM, "Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options", Hepatology, 52, pp.2192~2205 (2010)
  20. Choe BH, "Long-term therapeutic efficacy of lamivudine compared with interferon-alpha in children with chronic hepatitis B: the younger the better", J Pediatr Gastroenterol Nutr, 44, pp.92~98 (2007)
  21. 최병호, "소아 만성 B형 간염의 관리와 치료", Korean Journal of Pediatrics, 50(9), pp.823~834 (2007), 대한소아과학회
  22. Lok AS, "Chronic hepatitis B: update 2009", Hepatology, 50, pp.661~662 (2009)
  23. Leung N, "Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues", Hepatol Int, 2, pp.163~178 (2008)
  24. Kurbegov AC, "Hepatitis B therapy in children", Expert Rev Gastroenterol Hepatol, 3, pp.39~49 (2009)
  25. "The Criterias for the Medical Care Benefits"[URL]
  26. Kau A, "Treatment predictors of a sustained virologic response in hepatitis B and C", J Hepatol, 49, pp.634~651 (2008)
  27. Hong SP, "Long-term Efficacy and Durability of Lamivudine Therapy in Patients with Chronic Hepatitis B", Korean J Hepatol, 7, pp.423~431 (2001)
  28. 고홍, "Lamivudine Therapy for Korean Children with Chronic Hepatitis B", Yonsei Medical Journal, 48(6), pp.927~933 (2007), 연세대학교의과대학
  29. 이은혜, "소아 만성 B형 간염 환아에서 라미부딘의 치료 효과", Pediatric Gastroenterology, Hepatology & Nutrition, 11(2), pp.130~136 (2008), 대한소아소화기영양학회
  30. Lau GK, "Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B", N Engl J Med, 352, pp.2682~2695 (2005)
  31. Janssen HL, "Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial", Lancet, 365, pp.123~129 (2005)
  32. Chan HL, "A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone", Ann Intern Med, 142, pp.240~250 (2005)
  33. Marcellin P, "Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B", N Engl J Med, 351, pp.1206~1217 (2004)
  34. Schalm SW, "Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial", Gut, 46, pp.562~568 (2000)
  35. Sung JJ, "Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B", J Hepatol, 48, pp.728~735 (2008)
  36. Dikici B, "Current therapeutic approaches in childhood chronic hepatitis B infection: a multicenter study", J Gastroenterol Hepatol, 19, pp.127~133 (2004)
  37. Sokucu S, "Comparison of interferon monotherapy with interferon-lamivudine combination treatment in children with chronic hepatitis B", Indian J Gastroenterol, 25, pp.136~139 (2006)
  38. Carey I, "Monotherapy versus combination therapy for the treatment of chronic hepatitis B", Expert Opin Investig Drugs, 18, pp.1655~1666 (2009)
  39. Lee HW, "Lamivudine Maintenance Beyond One Year After HBeAg Seroconversion Is a Major Factor for Sustained Virologic Response in HBeAg-Positive Chronic Hepatitis B", HEPATOLOGY, 51, pp.415~421, JOHN WILEY & SONS INC
  40. 김정미, "HBeAg 음성 만성 B형 간염 소아청소년 환자에서 라미부딘의 적절 치료 기간 결정을 위한 장기 치료 경험", Pediatric Gastroenterology, Hepatology & Nutrition, 12(1), pp.23~29 (2009), 대한소아소화기영양학회
  41. 임형준, "약제 내성 B형간염에 대한 대처", 대한소화기학회지, 51(6), pp.346~359 (2008), 대한소화기학회
  42. Zoulim F, "Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection", Antiviral Res, 64, pp.1~15 (2004)
  43. Chu MA, "Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B", J Pediatr Gastroenterol Nutr (2012)
  44. 박기영, "소아 골반저 근실조에서 바이오피드백 치료의 유용성", Pediatric Gastroenterology, Hepatology & Nutrition, 10(1), pp.51~59 (2007), 대한소아소화기영양학회
  45. 김동준, "Telbivudine versus lamivudine in patients with chronic hepatitis B", NEW ENGLAND JOURNAL OF MEDICINE, 357(25), pp.2576~2588, MASSACHUSETTS MEDICAL SOC
  46. Yuen MF, "Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy", Hepatology, 34, pp.785~791 (2001)
  47. Fukai K ZK, "Association between lamivudine sensitivity and the number of substitutions in the reverse transcriptase region of the hepatitis B virus polymerase", J Viral Hepatol Int, 14, pp.661~666 (2007)
  48. Keeffe EB, "A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update", Gastroenterol Hepatol, 6, pp.1315~1341 (2008)
  49. Keeffe EB, "Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B", Clin Gastroenterol Hepatol, 5, pp.890~897 (2007)
  50. Reijnders JG, "Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues", J Hepatol, 52, pp.493~500 (2010)
  51. Ahn SH, "Prospective randomized trial of switching to entecavir in chronic hepatitis B patients with suboptimal virologic response to lamivudine: Interim analysis at 48 Weeks", Hepatology Int, 4, pp.53~ (2010)
  52. Hadziyannis SJ, "Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B", N Engl J Med, 348, pp.800~807 (2003)
  53. Hadziyannis SJ, "Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B", N Engl J Med, 352, pp.2673~2681 (2005)
  54. 황수경, "Lamivudine 내성 소아 청소년 만성 B형 간염에서 Adefovir의 치료 효과", Pediatric Gastroenterology, Hepatology & Nutrition, 11(2), pp.143~149 (2008), 대한소아소화기영양학회
  55. Yeon JE, "Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil", Gut, 55, pp.1488~1495 (2006)
  56. Lee YS, "Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy", HEPATOLOGY, 43(6), pp.1385~1391, JOHN WILEY & SONS INC
  57. Gaia S, "Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine", J Hepatol, 48, pp.540~547 (2008)
  58. Kim HJ, "Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy", J Gastroenterol Hepatol, 25, pp.1374~1380 (2010)
  59. Perrillo R, "Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus", Gastroenterology, 126, pp.81~90 (2004)
  60. Peters MG, "Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B", Gastroenterology, 126, pp.91~101 (2004)
  61. Rapti I, "Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B", Hepatology, 45, pp.307~313 (2007)
  62. Shin SR KK, "The DNA levels on initiation of adefovir as the important factor to get the more initial virological response in patients with lamivudine resistant hepatitis B", Hepatology, 48, pp.738~ (2008)
  63. Sherman M, "Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks", Hepatology, 48, pp.99~108 (2008)
  64. Osborn M, "Safety and efficacy of entecavir for the treatment of chronic hepatitis B", Infect Drug Resist, 4, pp.55~64 (2011)
  65. Chang TT, "A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B", N Engl J Med, 354, pp.1001~1010 (2006)
  66. 한광협, "Entecavir therapy for up to 96 weeks in patients with HBeAg-Positive chronic hepatitis B", GASTROENTEROLOGY, 133, pp.1437~1444, W B SAUNDERS CO-ELSEVIER INC
  67. Baldick CJ, "Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response", J Hepatol, 48, pp.895~902 (2008)
  68. Tenney DJ, "Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine", Antimicrob Agents Chemother, 48, pp.3498~3507 (2004)
  69. Villet S, "Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient", J Hepatol, 46, pp.531~538 (2007)
  70. Chung GE, "Add-On Adefovir Is Superior to a Switch to Entecavir as Rescue Therapy for Lamivudine-Resistant Chronic Hepatitis B", DIGESTIVE DISEASES AND SCIENCES, 56, pp.2130~2136, SPRINGER
  71. Ryu HJ, "Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B", J Med Virol, 82, pp.1835~1842 (2010)
  72. Yim HJ, "ADDING ADEFOVIR COMPARED WITH SWITCHING TO ENTECAVIR IN PATIENTS WITH LAMIVUDINE-RESISTANT CHRONIC HEPATITIS B (ACE STUDY) - A MULTICENTER PROSPECTIVE RANDOMIZED STUDY: 2 YEAR FINAL RESULTS", HEPATOLOGY, 54, pp.1060~1061, WILEY-BLACKWELL
  73. Lok AS, "Long-term safety of lamivudine treatment in patients with chronic hepatitis B", Gastroenterology, 125, pp.1714~1722 (2003)
  74. Allen MI, "Identification and characterization of mutations in hepatitis B virus resistant to lamivudine", Hepatology, 27, pp.1670~1677 (1998), Lamivudine Clinical Investigation Group
  75. Yoe S, "Incidence and risk factors of the YMDD mutation during lamivudine therapy in children with chronic hepatitis B", Asian Pan-Pacific Society of Pediatric Gastroenterology, Hepatology and Nutrition (APPSPGHAN), pp.106~ (2009)
  76. Sokal EM, "Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B", Hepatology, 43, pp.225~232 (2006)
  77. Yuki N, "Long-term histologic and virologic outcomes of acute self-limited hepatitis B", Hepatology, 37, pp.1172~1179 (2003)
  78. Fattovich G, "Natural history and prognosis of hepatitis B", Semin Liver Dis, 23, pp.47~58 (2003)

관련 논문AI추천

Current Role of Lamivudine Regarding Therapeutic Response and Resistance in Children with Chronic Hepatitis B권영오, 김여향, 박효정, 최병호, 탁원영, 홍석진대한소아소화기영양학회 · Pediatric Gastroenterology, Hepatology & Nutrition2013 · 제16권 제2호소아 만성 B형 간염 환아에서 라미부딘의 치료 효과김경모, 이은혜, 장주영대한소아소화기영양학회 · Pediatric Gastroenterology, Hepatology & Nutrition2008 · 제11권 제2호Lamivudine 내성 소아 청소년 만성 B형 간염에서 Adefovir의 치료 효과권영오, 김영미, 김정미, 김정옥, 박선민, 이지혜, 조민현, 최병호, 탁원영, 황수경대한소아소화기영양학회 · Pediatric Gastroenterology, Hepatology & Nutrition2008 · 제11권 제2호라미부딘 내성 소아 청소년 만성 B형 간염에서 Entecavir 치료 경험김정미, 조승만, 최병호, 추미애대한소아소화기영양학회 · Pediatric Gastroenterology, Hepatology & Nutrition2010 · 제13권 제1호인터페론 치료에 반응이 없었던 소아의 만성 B형 간염에 대한 라미부딘의 치료 효과김혜영, 박재홍, 연규민대한소아소화기영양학회 · Pediatric Gastroenterology, Hepatology & Nutrition2008 · 제11권 제2호The Rate of Conversion from Immune-tolerant Phase to Early Immune-clearance Phase in Children with Chronic Hepatitis B Virus Infection박효정, 주미애, 최병호, 최봉석, 홍석진대한소아소화기영양학회 · Pediatric Gastroenterology, Hepatology & Nutrition2014 · 제17권 제1호

이 간행물의 다른 논문 (9건)

Benign Recurrent Intrahepatic Cholestasis with a Single Heterozygote Mutation in the ATP8B1 GeneYoo Min Lee, 최연호, 김미진, Chang Seok Ki, Yun Seok Lee, Yoon Leepp. 22-126The Role of Inflammatory Mediators in the Pathogenesis of Nonalcoholic Fatty Liver Disease김준성pp. 74-78How to Manage the Pediatric Nutritional Support Team: Updates양혜란pp. 79-84Comparison of Four Commercial ELISA Kits and In-House Immunoblotting for Diagnosis of Helicobacter pylori Infection우향옥, 고경혁, 이우곤, Ji Sook Park, Hoar Lim Jeong, Yang‐Sook Jung, 전진수, 이광호, 서지현, 조명제, 윤희상, 임재영, 염정숙, 박찬후, 백승철pp. 85-90Cytomegalovirus Infection in Infantile Hepatitis나소영pp. 91-99
원문 보기